Precision Medicine Quarterly

Roche Diagnostics Q1 Sales Up 22 Percent

2022-04-25T11:09:25-05:00April 25th, 2022|

Roche on Monday said its diagnostics sales during the first quarter grew 22 percent year over year. Roche as a whole, including both its pharmaceutical and diagnostics divisions, had CHF 16.45 billion ($17.16 billion) in sales in the quarter, up 10 percent from CHF 14.93 billion in Q1 of 2021. At constant exchange rates, [...]

Next PrecisionFDA Challenge Takes on Indel Calling from Oncopanel Sequencing Data

2022-04-25T11:12:11-05:00April 25th, 2022|

The US Food and Drug Administration is preparing to open the next PrecisionFDA challenge, one looking at indel calling from oncopanel sequencing data. The PrecisionFDA program is working with the FDA's National Center for Toxicological Research (NCTR) to challenge the bioinformatics community to develop, validate, benchmark, and optimize indel calling pipelines from data produced [...]

Yourgene Health, Ambry Genetics Team on Genomic Services Under Extended Strategic Partnership

2022-04-25T11:16:47-05:00April 25th, 2022|

Yourgene Health said on Monday that it has extended its existing strategic partnership with Ambry Genetics with a new genomic services collaboration, which allows the companies mutual access to each other's technology and assays. Yourgene initially announced the partnership in 2021 but did not name Ambry at that time. The multi-year license and supply [...]

Tempus Sets Sights on Pathology Market With New Informatics, Research Network

2022-04-08T21:09:32-05:00April 8th, 2022|

Tempus has ventured into a new market segment with its recent introduction of Edge, a platform that provides pathologists with online access to artificial intelligence models to identify samples with potentially significant biomarkers with a single hematoxylin and eosin-stained slide. The platform is meant to help physicians decide whether to order genomic sequencing that [...]

New Research from the Caris Precision Oncology Alliance Finds Prognostic and Predictive Drug-Induced Gene Signatures for Colorectal Cancer Patients

2022-04-08T20:45:40-05:00April 8th, 2022|

- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used [...]

Blueprint Medicines Expands Trials of EGFR Inhibitors in NSCLC

2022-04-08T20:37:15-05:00April 8th, 2022|

Blueprint Medicines on Friday announced a clinical trial collaboration with AstraZeneca to study its EGFR inhibitors BLU-945 and BLU-701 in combination with AstraZeneca's Tagrisso (osimertinib) in non-small cell lung cancer. Blueprint will begin a trial cohort in its ongoing Phase I/II SYMPHONY trial to assess BLU-945 in combination with Tagrisso in patients with second-line [...]

Single-Cell Sequencing Study Uncovers Blood Cell Type-Specific Features

2022-04-08T20:32:18-05:00April 8th, 2022|

With the help of single-cell RNA sequencing, a University of California, San Francisco-led team teased out some of the processes and regulatory pathways behind systemic lupus erythematosus (SLE), profiling shifts in blood cell composition and the expression of distinct blood cell types in more than 150 individuals with the heterogeneous autoimmune condition. "Single-cell sequencing [...]

Go to Top